These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in direct acting antiviral naive patients. Grammatikos G; Jabara CB; Ahmad MQ; Herrmann E; Zeuzem S; Welsch C Antivir Ther; 2014; 19(5):455-61. PubMed ID: 24457994 [TBL] [Abstract][Full Text] [Related]
11. Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors. Ehrenberg AE; Schmuck B; Anwar MI; Gustafsson SS; Stenberg G; Danielson UH J Enzyme Inhib Med Chem; 2014 Dec; 29(6):868-76. PubMed ID: 24517372 [TBL] [Abstract][Full Text] [Related]
12. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Vallet S; Viron F; Henquell C; Le Guillou-Guillemette H; Lagathu G; Abravanel F; Trimoulet P; Soussan P; Schvoerer E; Rosenberg A; Gouriou S; Colson P; Izopet J; Payan C; Antivir Ther; 2011; 16(7):1093-102. PubMed ID: 22024525 [TBL] [Abstract][Full Text] [Related]
13. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. Susser S; Vermehren J; Forestier N; Welker MW; Grigorian N; Füller C; Perner D; Zeuzem S; Sarrazin C J Clin Virol; 2011 Dec; 52(4):321-7. PubMed ID: 21924672 [TBL] [Abstract][Full Text] [Related]
14. Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy. Morsica G; Bagaglio S; Uberti-Foppa C; Galli L; Lazzarin A J Acquir Immune Defic Syndr; 2009 May; 51(1):106-8. PubMed ID: 19390331 [No Abstract] [Full Text] [Related]
15. Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus. Holland-Staley CA; Kovari LC; Golenberg EM; Pobursky KJ; Mayers DL Arch Virol; 2002 Jul; 147(7):1385-406. PubMed ID: 12111414 [TBL] [Abstract][Full Text] [Related]
16. Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method. Besse B; Coste-Burel M; Bourgeois N; Feray C; Imbert-Marcille BM; André-Garnier E J Virol Methods; 2012 Oct; 185(1):94-100. PubMed ID: 22728274 [TBL] [Abstract][Full Text] [Related]
17. Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients. Vallet S; Gouriou S; Nousbaum JB; Legrand-Quillien MC; Goudeau A; Picard B J Med Virol; 2005 Apr; 75(4):528-37. PubMed ID: 15714495 [TBL] [Abstract][Full Text] [Related]
18. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Tong X; Chase R; Skelton A; Chen T; Wright-Minogue J; Malcolm BA Antiviral Res; 2006 Jun; 70(2):28-38. PubMed ID: 16448708 [TBL] [Abstract][Full Text] [Related]
19. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates. Sheaffer AK; Lee MS; Hernandez D; Chaniewski S; Yu F; Falk P; Friborg J; Zhai G; McPhee F Antivir Ther; 2011; 16(5):705-18. PubMed ID: 21817192 [TBL] [Abstract][Full Text] [Related]
20. HCV-1b intra-subtype variability: Impact on genetic barrier to protease inhibitors. Ferraro D; Urone N; Di Marco V; Craxì A Infect Genet Evol; 2014 Apr; 23():80-5. PubMed ID: 24508244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]